Skip to main content
. Author manuscript; available in PMC: 2012 Nov 21.
Published in final edited form as: Vaccine. 2011 Oct 12;29(50):9361–9367. doi: 10.1016/j.vaccine.2011.09.133

Figure 1. Exosomal Adenoviral Vectors.

Figure 1

A) Design of adenoviral vectors encoding CEA/ECD and HER2/ECD exosomal constructs and controls. B) Ad transduced (MOI=2000) JAWSII and bmDCs supernatant CEA expression at 24 and 48 hpi. C and D) Ad-transduced (MOI=2000) JAWSII cells 24hpi (C) and 48hpi (D) supernatants were assessed using an exosome-specific ELISA, which employed a CD81 capture antibody to isolate exosomes and CEA-specific detection antibody (C) and HER2-specific detection antibody (D) to assess exosomal CEA andHER2 expression. In all experiments, * and ** denotes conditions that showed p<0.05 and p<0.01 respectively, compared to control Ad-LacZ transduction and # and ## denote conditions that showed p<0.05 and p<0.01 respectively to Ad-CEA/ECD or Ad-HER2/ECD treatment. N=3 and error bars=SD.